Classifying Cytogenetics in Patients with Acute Myelogenous Leukemia in Complete Remission Undergoing Allogeneic Transplantation: A Center for International Blood and Marrow Transplant Research Study  by Armand, Philippe et al.
From the
tute, B
ology
Biosta
Trans
ter fo
Milwa
tute,
Temp
delph
tation
Hema
MN;
Hosp
NY; 1
Medic
Onco
12Dep
Ontar
derbil
Medic
of He
Greno
huis M
tology
Germ
Diego
King
Saudi
Malig
21Dep
22Dep
Bosto
Sinai
Osped
of Pe
(MAC
280Classifying Cytogenetics in Patients with Acute
Myelogenous Leukemia in Complete Remission
Undergoing Allogeneic Transplantation: A Center
for International Blood and Marrow Transplant
Research Study
Philippe Armand,1 Haesook T. Kim,2 Mei-Jie Zhang,3 Waleska S. Perez,4 Paola S. Dal Cin,5
Thomas R. Klumpp,6 Edmund K. Waller,7 Mark R. Litzow,8 Jane L. Liesveld,9
Hillard M. Lazarus,10 Andrew S. Artz,11 Vikas Gupta,12 Bipin N. Savani,13 Philip L. McCarthy,14
Jean-Yves Cahn,15 Harry C. Schouten,16 J€urgen Finke,17 Edward D. Ball,18 Mahmoud D. Aljurf,19
Corey S. Cutler,20 Jacob M. Rowe,21 Joseph H. Antin,22 Luis M. Isola,23 Paolo Di Bartolomeo,24
Bruce M. Camitta,25 Alan M. Miller,26 Mitchell S. Cairo,27 Keith Stockerl-Goldstein,28
Jorge Sierra,29 M. Lynn Savoie,30 Joerg Halter,31 Patrick J. Stiff,32 Chadi Nabhan,33
Ann A. Jakubowski,34 Donald W. Bunjes,35 Effie W. Petersdorf,36 Steven M. Devine,37
Richard T. Maziarz,38 Martin Bornhauser,39 Victor A. Lewis,40 David I. Marks,41
Christopher N. Bredeson,42 Robert J. Soiffer,43 Daniel J. Weisdorf441Dept of Medical Oncology, Dana-Farber Cancer Insti-
oston, MA; 2Dept of Biostatistics and Computational Bi-
, Dana-Farber Cancer Institute, Boston, MA; 3Dept of
tistics, Center for International Blood and Marrow
plant Research,Milwaukee,WI; 4Dept of Medicine, Cen-
r International Blood and Marrow Transplant Research,
ukee, WI; 5Dept of Medicine, Dana-Farber Cancer Insti-
Boston, MA; 6Bone and Marrow Transplant Program,
le University Bone Marrow Transplant Program, Phila-
ia, PA; 7Dept of Bone and Marrow Stem Cell Transplan-
, Emory University Hospital, Atlanta, GA; 8Dept of
tology and Internal Medicine, Mayo Clinic, Rochester,
9Dept of Hematology and Oncology, Strong Memorial
ital–University of Rochester Medical Center, Rochester,
0Dept of Medical Oncology, University Hospitals Case
al Center, Cleveland, OH; 11Dept of Hematology and
logy, University of Chicago Hospitals, Chicago, IL;
t of Hematology, Princess Margaret Hospital, Toronto,
io, Canada; 13Dept of Hematology and Oncology, Van-
t University Medical Center, Nashville, TN; 14Dept of
ine, Roswell Park Cancer Institute, Buffalo, NY; 15Dept
matology, Hospital A. Michallon, CHU de Grenoble,
ble, France; 16Dept of Medicine, Academische Zieken-
astricht, Maastricht, The Netherlands; 17Dept of Hema-
and Oncology, Universitatsklinikum Freiburg, Freiburg,
any; 18Dept of Medicine, University of California San
Medical Center, La Jolla, CA; 19Dept of Hematology,
Faisal Specialist Hospital and Research Center, Riyadh,
Arabia; 20Dept of Medical Oncology and Hematologic
nancies, Dana-Farber Cancer Institute, Boston, MA;
t of Hematology, RambamMedical Center, Haifa, Israel;
t of Medical Oncology, Dana-Farber Cancer Institute,
n, MA; 23Dept of Hematology and Oncology, Mount
Medical Center, New York, NY; 24Dept of Hematology,
ale Civile BMT Center Pescara, Pescara, Italy; 25Dept
diatrics, Midwest Athletes Against Childhood Cancer
C) Fund Center for Cancer and Blood Disorders, Child-
ren’s Hospital and Medical College of Wisconsin, Milwaukee,
WI; 26Dept of Oncology, Baylor University Medical Center,
Dallas, TX; 27Dept of Pediatric Hematology and Oncology,
Morgan Stanley Children’s Hospital of New York–Presbyter-
ian, Columbia University Medical Center, New York, NY;
28Dept of Bone Marrow Transplant, Washington University
School of Medicine, St. Louis, MO; 29Dept of Hematology,
Hospital de la Santa Creu I Sant Pau, Barcelona, Spain;
30Dept of Medical Oncology, Tom Baker Cancer Center, Cal-
gary, Alberta, Canada; 31Dept of Internal Medicine, University
Hospital Basel, Basel, Switzerland; 32Dept of Hematology and
Oncology, Loyola University Medical Center, Maywood, IL;
33Dept of Hematology and Oncology, Advocate Lutheran Gen-
eral Hospital, Park Ridge, IL; 34Dept of Hematologic Oncol-
ogy, Memorial Sloan-Kettering Cancer Center, New York,
NY; 35Dept of Medicine, Universitatsklinikum Ulm, Ulm,
Germany; 36Dept of Oncology, Fred Hutchinson Cancer Re-
search Center, Seattle, WA; 37Dept of Blood and Marrow
Transplant, Ohio State Medical Center, James Cancer Center,
Columbus, OH; 38Dept of Bone Marrow Transplant, Oregon
Health and Science University, Portland, OR; 39Dept of Medi-
cine, Universitatsklinikum Carl Gustav Carus, Dresden,
Germany; 40Dept of Hematology andOncology, Alberta Child-
ren’s Hospital, Calgary, Alberta, Canada; 41Dept of Hematol-
ogy, Bristol Children’s Hospital, Bristol, U.K.; 42Dept of
Medicine, Froedert Memorial Lutheran Hospital, Milwaukee,
WI; 43Dept ofHematologicOncology,Dana-Farber Cancer In-
stitute, Boston, MA; and 44Dept of Medicine, University of
Minnesota Medical Center, Minneapolis, MN.
Financial disclosure: See Acknowledgments on page 288.
Correspondence and reprint requests: Philippe Armand, M.D.,
Ph.D., Dana-Farber Cancer Institute, 44 Binney Street, Boston,
MA 02115 (e-mail: parmand@partners.org).
Received May 26, 2011; accepted July 27, 2011
 2012 American Society for Blood and Marrow Transplantation
1083-8791/$36.00
doi:10.1016/j.bbmt.2011.07.024
Biol Blood Marrow Transplant 18:280-288, 2012 281AML Cytogenetics Classification for HCTCytogenetics play a major role in determining the prognosis of patients with acute myelogenous leukemia
(AML). However, existing cytogenetics classifications were developed in chemotherapy-treated patients
and might not be optimal for patients undergoing allogeneic hematopoietic cell transplantation (HCT).
We studied 821 adult patients reported to the Center for International Blood and Marrow Transplant
Research (CIBMTR) who underwent HCT for AML in first or second complete remission between 1999
and 2004. We compared the ability of the 6 existing classifications to stratify patients by overall survival.
We then defined a new scheme specifically applicable to patients undergoing HCTusing this patient cohort.
Under this scheme, inv(16) is favorable, a complex karyotype (4 or more abnormalities) is adverse, and all
other classified abnormalities are intermediate in predicting survival after HCT (5-year overall survival,
64%, 18%, and 50%, respectively; P 5 .0001). This scheme stratifies patients into 3 groups with similar non-
relapse mortality, but significantly different incidences of relapse, overall and leukemia-free survival. It applies
to patients regardless of disease status (first or second complete remission), donor type (matched related or
unrelated), or conditioning intensity (myeloablative or reduced intensity). This transplantation-specific clas-
sification could be adopted for prognostication purposes and to stratify patients with AML and karyotypic
abnormalities entering HCT clinical trials.
Biol Blood Marrow Transplant 18: 280-288 (2012)  2012 American Society for Blood and Marrow TransplantationKEY WORDS: AML, SCT, KaryotypeINTRODUCTION
The importance of cytogenetics in determining out-
come in patients with acute myelogenous leukemia
(AML) is well established [1,2]. Several collaborative
groups have proposed classification schemes to stratify
patients by leukemia karyotype, based on retrospective
studies of large independent patient cohorts. The most
commonly used groupings are those of the Medical
Research Council (MRC) [3,4] (now the National
Cancer Research Institute), the Cancer And Leukemia
GroupB (CALGB) [5], the SouthwestOncologyGroup
(SWOG)/ Eastern Cooperative Oncology Group
(ECOG) [6], and the European Organization for Re-
search and Treatment of Cancer (EORTC)/ Gruppo
Italiano Malattie Ematologiche Ddell’ Adulto
(GIMEMA) [7]. More recently, Breems et al. [8] re-
ported that a monosomal karyotype (MK) is a predictor
of very poor outcome in AML. However, most patients
in the foregoing studies were treated with conventional
chemotherapy rather than allogeneic hematopoietic cell
transplantation (HCT).
HCT is an important treatment modality for se-
lected patients with AML, underscoring the need to
understand the role of cytogenetics in determining
HCT outcome. Although cytogenetics apparently
retain their prognostic relevance in the setting of
HCT [6,7,9-11], so far there is no validated HCT-
specific cytogenetics classification scheme. Because
the benefit of HCT largely depends on an immuno-
logic graft-versus-tumor effect, it is conceivable that
a given karyotypic subtype of AML might behave
differently after HCT than after conventional chemo-
therapy. Therefore, classification schemes based on
series of patients treated with chemotherapy might
not apply optimally to transplanted patients.An HCT-specific cytogenetics grouping scheme
would be useful to aid prognostication, help guide
treatment decisions, stratify patients entering clinical
trials, and compare reported HCT outcomes across
studies or centers. We previously proposed such a
classification scheme based on a cohort of patients
undergoing transplantation at Dana-Farber Cancer
Institute/Brigham andWomen’s Hospital (henceforth
referred to as the DFCI schema) [11], but this scheme
has not been validated in an independent cohort.
Consequently, we performed a retrospective study
through the Center for International Blood and Mar-
row Transplant Research (CIBMTR) with 2 aims: to
validate the previous report by comparing the perfor-
mance of the 6 existing classification schemes in an
independent cohort of HCT patients, and to derive a
new grouping schema based on this multicenter cohort.METHODS
Data Source
The CIBMTR is a research organization compris-
ing more than 500 transplantation centers worldwide
that contribute detailed data on consecutive allogeneic
HCT. Patients are followed longitudinally, with yearly
follow-up. Computerized checks for errors, physician
reviews of submitted data, and onsite audits of parti-
cipating centers ensure data quality. All patients regis-
tered with the National Marrow Donor Program
(NMDP) were retrospectively contacted, and informed
consent was obtained from surviving patients in accor-
dance with the Declaration of Helsinki for participation
in the NMDP research program. Informed consent was
waived by theNMDP Institutional ReviewBoard for all
Table 1. Baseline Patient Characteristics
Variable
Number of patients 821
Number of centers 49
Age in years, median (range) 41 (18-74)
Age distribution, yr, n (%)
<40 366 (45)
40-49 220 (27)
50-59 167 (20)
60-64 48 (6)
282 Biol Blood Marrow Transplant 18:280-288, 2012P. Armand et al.deceased patients. Surviving patients who did not pro-
vide signed informed consent to allow analysis of their
clinical data were excluded. To adjust for the potential
bias introduced by exclusion of nonconsenting surviv-
ing patients, a corrective action plan modeling process
randomly excluded the same percentage of deceased pa-
tients using a biased coin randomization with exclusion
probabilities based on characteristics associated with
not providing consent for use of the data in survivors.65+ 20 (2)
Sex, n (%)
Male 457 (56)
Female 364 (44)
Therapy-related disease, n (%)* 36 (4)
WBC count at diagnosis,  109/L, n (%)
<20 411 (50)
20-50 138 (17)
>50 174 (21)
Data missing 98 (12)
Disease status at HCT, n (%)
CR1 498 (61)
CR2 322 (39)
Duration of CR1, n (%)†
<6 months 67 (21)
6-12 months 93 (29)
>12 months 110 (34)
Data missing 52 (16)
Karnofsky performance score at SCT, n (%)
$90% 597 (73)
<90% 171 (21)
Data missing 53 (6)
Donor category, n (%)‡
MRD 390 (48)
Non-MRD 431 (52)
Well-matched URD 194 (24)
Partially matched URD 110 (13)
Mismatched URD 110 (13)
URD match unknown 50 (6)
Mismatched relative 40 (5)
Graft source, n (%)
Peripheral blood 537 (65)
Bone marrow 284 (35)
Conditioning, n (%)
Myeloablative 612 (75)
Nonmyeloablative/RIC 209 (25)
GVHD prophylaxis, n (%)
Calcineurin inhibitor–based 768 (94)
T cell depletion 32 (4)
Other 21 (3)
CMV serostatus, recipient or donor +, n (%)§ 619 (75)Patient Selection
We included all patients age 18 years and older
who underwent transplantation for AML in first com-
plete remission (CR1) or second complete remission
(CR2) between 1999 and 2004 at CIBMTR centers
that treated more than 20 eligible patients during this
period. CR was defined as the absence of blasts in
peripheral blood and\5% blasts in marrow, with cel-
lular marrow and normal complete blood count. No
information was available on CR with platelet count
\100,000/mL or CR with insufficient hematologic
recovery status. Patients with acute promyelocytic leu-
kemia or preexisting myelodysplastic syndrome were
excluded (because cytogenetics for these patients may
be better grouped according to a myelodysplastic syn-
drome–specific classification [11,12]), as were patients
with t(9;22) AML (given the difficulty of distinguishing
this disease from blast crisis chronic myelogenous
leukemia in a registry setting). Patients who
underwent previous autologous progenitor cell
transplantation for AML were excluded, as were
patients who received a transplant from syngeneic or
cord blood donors. Patients who underwent trans-
plantation at Dana-Farber/Brigham and Women’s
Hospital were ineligible, because they were used to
derive the DFCI scheme. Finally, all patients for
whom cytogenetic information was missing or not
obtainable were excluded.Sex match, n (%)¶
Female to male 180 (22)
Male to female 202 (25)
Female to female 161 (20)
Male to male 277 (34)
Year of HCT, median (range) 2002 (1999-2004)
Months of follow-up, median (range) 61 (3-122)
Percentages may not add up to 100 because of rounding.
*Data missing on 4 patients.
†For patients in CR2.
‡Classified according to Weisdorf et al. [17].
§Data missing on 21 patients.
¶Data missing on 3 patients.Cytogenetics
We reviewed all available primary cytogenetics re-
ports for patients with abnormal karyotypes (available
for 92% of patients), with the help of an expert cytoge-
neticist Dr. Paola S. Dal Cin (P.D.C.). Patients with
a reported normal karyotype were not reviewed. The
latest available tumor karyotype (ie, at diagnosis for pa-
tients in CR1 and at relapse for patients in CR2 when
available) was used for this analysis. Cytogenetics were
classified according to each of the existing schemes
(Supplementary Table 1), with the followingmodifica-
tion: Patients with t(8;21) or inv(16) were classified as
favorable under the MK scheme, even though this
scheme does not specifically define a favorable sub-
group.Study Endpoints, Definitions, and Statistical
Analysis
The primary endpoint for this analysis was overall
survival (OS) after HCT, defined as the time from
transplantation to death, with surviving patients
Table 2. Cytogenetics
Abnormality
CR1
Patients
CR2
Patients
Number of patients 499 322
Normal, n (%) 281 (56) 215 (67)
t(8;21), n (%) 17 (3) 24 (7)
Isolated 11 12
With del(9q) or complex karyotype 2 8
With other abnormalities 4 4
Inv(16)-related (inv(16) or t(16;16)), n (%) 15 (3) 29 (9)
Isolated 7 20
With complex karyotype 6 4
With other abnormalities 2 5
Abnormal 7, n (%)* 33 (7) 12 (4)
-7 17 5
del(7q) 10 5
der(1;7)(q10;p10) 2 0
Other 7q abnormality 4 2
Abnormal 5, n (%)† 28 (6) 3 (1)
-5 7 0
del(5q) 17 3
Other 5q abnormality 4 0
11q23 abnormality, n (%) 37 (7) 10 (3)
t(6;11) 6 3
t(9;11) 14 2
t(10;11) 2 0
t(11;19) 5 1
Other 11q23 abnormality 10 4
3q abnormality, n (%) 11 (2) 3 (1)
t(3;3) 1 0
inv(3q) 2 0
t(3;5) 0 1
Other 3q abnormality 8 2
Trisomy/tetrasomy, n (%)
Trisomy 8 31 (6) 13 (4)
Trisomy 21 6 (1) 4 (1)
Other trisomy 24 (5) 9 (3)
Tetrasomy 8 2 (0) 2 (1)
Tetrasomy 21 1 (0) 0 (0)
Monosomy, n (%)
Autosomal (except 5, 7 or 17) 29 (6) 7 (2)
-X 3 (1) 1 (0)
-Y 5 (1) 7 (2)
17p abnormality, n (%) 18 (4) 3 (1)
del(17p) 1 0 (0)
Other (including monosomy 17) 17 3 (1)
12p abnormality, n (%) 10 (2) 4 (1)
del(12p) 2 2
add(12p) 2 1
t(4;12) 0 1
t(5;12) 1 0
Other 12p abnormality 5 0
Other, n (%)
t(1;19) 1 (0) 0 (0)
t(6;9) 7 (1) 2 (1)
inv(6) 1 (0) 1 (0)
t(8;16) 3 (1) 0 (0)
del(9q) 4 (1) 8 (2)
dup(11q) 0 (0) 0 (0)
del(11q23) 8 (2) 0 (0)
del(16q22) 1 (0) 0 (0)
del(20q) 2 (0) 2 (1)
del(21q) 1 (0) 0 (0)
Tetraploid 0 (0) 1 (0)
Monosomal karyotype, n (%)‡ 31 (6) 6 (2)
Complex karyotype
($3 abnormalities), n (%)
67 (13) 29 (9)
3 abnormalities 16 (3) 9 (3)
4 abnormalities 17 (3) 7 (2)
5 abnormalities 34 (7) 13 (4)
Number of abnormalities, median (range) 5 (3-15) 4 (3-9)
Percentages may not add up to 100 because of rounding and because
some patients have more than one abnormality (see Methods).
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Leukemia-free survival (LFS) was defined as the time
from transplantation to death or relapse, with surviv-
ing patients censored at the last time they were re-
ported alive and leukemia-free. Nonrelapse mortality
(NRM) was defined as death without evidence of leu-
kemia recurrence. OS and LFS were calculated using
the Kaplan-Meier method. The log-rank test was
used for comparisons of Kaplan-Meier curves. Cumu-
lative incidence curves for nonrelapse death and re-
lapse were constructed reflecting time to relapse and
time to NRM as competing risks. The difference be-
tween cumulative incidence curves in the presence of
a competing risk was tested using the Gray method
[13]. Potential prognostic factors for OS, LFS, relapse,
and NRM were examined in the proportional hazards
model as well as in the competing-risks regression
model [14]. The proportional hazards assumption
was tested for each variable of interest. Interaction
terms, including interaction with time, were examined
in the proportional hazards regression model. To
compare the performance of classification systems,
we calculated the difference in the Akaike information
criterion (AIC) between the full model and a model
that did not include cytogenetics. We also calculated
the c-index [15] for censored OS data and the Inte-
grated Brier Score (IBS) [16] for models using each
of the various grouping schemes. The analyses were
conducted using Matlab version 6.5 (Mathworks, Na-
tick, MA), SAS version 9.2 (SAS Institute, Cary, NC),
and R version 2.18.1.RESULTS
Patient Characteristics and Cytogenetics
The baseline characteristics of the 821 patients are
summarized in Table 1. The median patient age was
41 years (range, 18-74 years). Four percent of the pa-
tients had therapy-related leukemia. Sixty-one percent
underwent transplantation in CR1, and 39% did so in
CR2; 48% had a matched related donor (MRD), and
24% had a well-matched unrelated donor (URD) [17].
Nearly two-thirds received peripheral blood stem cells,
and three-quarters received a myeloablative condi-
tioning regimen. Graft-versus-host disease (GVHD)
prophylaxis regimens mainly (94%) consisted of a calci-
neurin inhibitor–based regimen. Median follow-up was*Of the patients with monosomy 7, 4 had no other abnormalities, 4
had 1 other abnormality, and the remainder had a complex karyotype
(3-15 abnormalities).
†Other than for 2 patients who had isolated del(5q), all abnormalities of
chromosome 5 were associated with other abnormalities; all of the pa-
tients with monosomy 5 had complex karyotypes (5-15 abnormalities).
‡Defined as 2 or more autosomal monosomies or a single autosomal
monosomy with 1 or more structural abnormalities (clonal deletion,
addition, inversion, or translocation).
Table 3. Comparison of Existing Cytogenetic Schemata on the Entire Cohort
Grouping Scheme
Patients Not
Classifiable, n (%) Model Fit Score* c-Index† IBS‡
HR for Favorable
(P Value)§
HR for Adverse
(P Value)§
MRC¶ 0 (0) 56.3 0.53 0.154 0.8 (.13) 1.8 (.0001)
CALGB 68 (8) 58.5 0.52 0.155 0.6 (.02) 1.5 (.001)
SWOG/ECOG 51 (6) 49.0 0.53 0.154 0.7 (.19) 1.4 (.010)
EORTC/GIMEMA 0 (0) 50.0 0.53 0.153 0.8 (.40) 1.5 (.003)k
DFCI 5 (1) 60.0 0.55 0.153 0.7 (.080) 1.8 (<.0001)
MK 0 (0) 51.3 0.52 0.155 0.8 (.20) 1.9 (.001)
Comparisons were performed on the subset of 749 patients classifiable under all schemata, in a multivariable model that included patient age, sex,
therapy-related disease, WBC at diagnosis, disease status, duration of CR1, conditioning intensity, GVHD prophylaxis regimen, KPS score, graft source,
donor category, and CMV serostatus.
*Defined as the difference in AIC between the model without covariates and the model with covariates; the greater the difference, the better the model
fit.
†Defined as the generalization of the area under the curve for censored survival data using cytogenetics risk group assignment as a predictor, with
a higher proportion indicating a better fit.
‡Integrated Brier Score, which measures prediction error; the lower the score, the better the prediction ability.
§Intermediate risk is the reference group for both comparisons. HR denotes hazard ratio for mortality.
¶The model fit using the revised MRC classification [4] was inferior to that using the original classification [3] (not shown).
kFor the very adverse group. Adverse group in this schema was comparable to the intermediate group (HR, 1.1; P 5 .60).
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sented in Table 2. Fifty-six percent of patients who
underwent transplantation in CR1 and 67% of those
who did so in CR2 had a normal karyotype. Six percent
of the patients in CR1 and 16% of those in CR2 had
core-binding factor (CBF) AML, and 13% of the pa-
tients in CR1 and 9% of those in CR2 had a complex
karyotype with at least 3 abnormalities.Table 4. CIBMTR Cytogenetics Grouping Schema
Group Abnormality HR* P Value
Favorable Inv(16) (without
complex karyotype)
0.5 .030
Intermediate Normal 1.0 Reference
t(8;21) 1.1 .80
11q23 abnormality 1.1 .70
Trisomy/tetrasomy 8 1.2 .50
Abnormal 5 or 7 1.3 .30
Complex (3 abnormalities) 1.1 .70
Inv(16) with complex karyotype 1.0 1.00
Other abnormalities† 1.1 .70
Adverse Complex (4 abnormalities) 1.5 .10
Complex ($5 abnormalities) 2.3 <.0001
*Compared with normal karyotype.
†Except for abn12p, abn3q, del(9q), t(1;19), t(9;22), t(6;9), which are not
classified in this scheme.Model Comparison for OS
The 5-yearOS for the entire cohort was 48% (95%
confidence interval [CI]: 44%-51%). We built Cox
models for OS using cytogenetics (grouped according
to the MRC scheme), considering the following cova-
riates: year of transplantation, age, patient and donor
sex, disease status at HCT, duration of CR1 (for
patients in CR2), therapy-related disease, white blood
cell (WBC) count at diagnosis, Karnofsky Perfor-
mance Score (KPS) at HCT, donor category [17],
cytomegalovirus (CMV) serostatus, conditioning
intensity, GVHD prophylaxis regimen, graft source,
andCD34 cell dose. Among these factors, cytogenetics,
therapy-related disease, KPS (above or below 90%),
duration of CR1, donor category, donor sex, and graft
source were significant for OS (not shown). The results
did not change significantly when cytogenetics were
categorized using another of the existing schemes.
We compared the ability of the 6 existing cytoge-
netics grouping schemes to stratify patients for OS, us-
ing 3 different metrics for this comparison: (1) the AIC
difference, which measures the improvement in model
fit from the addition of the covariate of interest (in this
case, cytogenetics risk group), with a better fit indi-
cated by a higher difference; (2) the c-index, which is
a generalization of the area under the receiver operat-
ing curve for censored survival data, using the cytoge-
netics risk assignment as a predictor, with a better
predictor indicated by a higher proportion (and anexpected value of 0.5 for random prediction); and (3)
the IBS, a measure of prediction error, with a better
predictor indicated by a lower score. The results are
presented in Table 3. The DFCI scheme provided
the greatest AIC difference, the highest c-index, and
the lowest IBS (although the differences were small
and likely insignificant). Of note, in the Cox model,
cytogenetics was the most influential factor (ie,
highest hazard ratio [HR] for mortality) for OS.Derivation of a CIBMTR Scheme
We then used the present cohort to derive a new
grouping scheme. For this, we excluded 13 patients
with 2 abnormalities (to avoid making assumptions
about the hierarchy of different abnormalities) and
only included karyotypic abnormalities present in at
least 20 patients, thereby restricting our analysis to
787 patients. We determined the HR for mortality
for each cytogenetic abnormality relative to normal
karyotype using the same Cox model used earlier for
model comparison. To better define the outcome of
patients with complex karyotype, we divided this
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ties. The results, presented in Table 4, allowed us to
define 3 distinct risk groups: a favorable group with
inv(16) (5% of patients), an adverse group with a com-
plex karyotype with$4 abnormalities (9% of patients),
and an intermediate group comprising normal karyo-
type and all other classified abnormalities (86% of pa-
tients). Even though the P value associated with 4
abnormalities did not reach statistical significance for
OS, theHR for mortality was 1.5, and the LFS of those
patients was significantly worse than that of patients
with normal karyotype (HR, 1.6; P 5 .046), justifying
its place in the adverse group. The OS of patients with
t(6;9) was significantly worse than that of patients with
normal karyotype (HR, 2.7; P5 .049), but this was not
included in the final classification, given the small
number of patients with this abnormality. In this anal-
ysis, neither isolated t(8;21) nor t(8;21) in conjunction
with other abnormalities was significantly different
from normal karyotype. In addition, within the com-
plex karyotype group, no specific abnormality ap-
peared to affect outcome with the exception of
inv(16), which in the presence of a complex karyotype
($4 abnormalities) behaved like an intermediate-risk
abnormality (HR relative to normal karyotype, 1.0;
P 5 1.0). Finally, within the adverse group, an MK
genotype was not associated with significantly worse
outcome (HR, 1.2; P 5 .50). Using the same method
to derive a grouping scheme for LFS yielded the
same results.
Performance of the CIBMTR Schema
We then compared the performance of the new
CIBMTR cytogenetics grouping scheme and that ofFigure 1. Transplantation outcomes for patients classified by theCIBMTRgrouthe existing schemes, again restricting the comparison
to patients classifiable under all schemes (727 patients).
Overall, the new scheme outperformed all others (AIC
difference, 67.6, compared with the next-best score of
61.5 for DFCI schema; IBS, 0.151, compared with
0.153 for DFCI; c-index 0.54, compared with 0.54
for DFCI). Because there were too few patients in
this dataset to perform internal validation studies, we
used our previous (and entirely independent) DFCI
cohort [11] as a validation group, restricting it to the
189 patients who met eligibility criteria for the present
study. The CIBMTR scheme could stratify patients
into 3 groups with significantly different OS (5-year
OS, 76% for the favorable group, 41% for the interme-
diate group, and 23% for the adverse group; P5 .019).
The OS, LFS, cumulative incidence of relapse
(CIR), and NRM for all classifiable patients based on
this new CIBMTR scheme are shown in Figure 1.
The 5-year OS was 64% (95% CI, 47%-77%) for
the favorable group, 50% (95% CI, 46%-54%) for
the intermediate group, and 18% (95% CI, 9%-
28%) for the adverse group (P 5 .0001). In the multi-
variate model, the HR for mortality of the favorable
group compared with the intermediate group was 0.7
(P 5 .03), and that of the adverse group compared
with the intermediate group was 1.9 (P\ .0001). Ab-
normal karyotypes included in the intermediate group
had a similar outcome to normal karyotype (5-yearOS,
46% versus 51%; P 5 .50). The 5-year LFS was 58%
(95% CI, 40%-72%) for the favorable group, 45%
(95% CI, 41%-49%) for the intermediate group, and
16% (95% CI, 8%-26%) (P\ .0001) for the adverse
group. The CIR also differed significantly among
the 3 groups (19%, 29%, and 51% respectively;ping scheme. (A)OS. (B) LFS. (C)CIR. (D)Cumulative incidence ofNRM.
Figure 2. OS of patients classified according to the CIBMTR schema, stratified by disease status. (A) Patients undergoing transplantation in CR1.
(B) Patients undergoing transplantation in CR2.
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33%; P 5 .30). The significant association of cytoge-
netic risk group with LFS and CIR was confirmed in
multivariate models; the HR for death or relapse in
the favorable group compared with the intermediate
group was 0.6 (P5 .055), and that in the adverse group
compared with the intermediate group was 1.9 (P\
.0001). The HR for relapse in the favorable group
compared with the intermediate group was 0.5 (P 5
.067), and that in the adverse group compared with
the intermediate group was 2.0 (P \ .0001). Con-
versely, cytogenetics risk group did not significantly
affect NRM (HR, 0.9 for favorable compared with in-
termediate [P 5 .80] and 1.2 for adverse compared
with intermediate [P 5 .40]).
As shown in Figures 2-4, the CIBMTR scheme
applied to patients regardless of disease status (CR1
versus CR2; see Figure 2), donor category (MRD versus
URD; see Figure 3), or conditioning intensity (ablative
versus reduced-intensity conditioning [RIC]; see
Figure 4). The log-rank P value in the RIC subgroup
did not reach statistical significance (P 5 .063), but
this is likely because of small patient numbers, and the
differences in LFS remained significant (P 5 .025,
log-rank test).DISCUSSION
We propose a new cytogenetics grouping scheme
specifically applicable to patients with AML under-Figure 3. OS of patients classified according to the CIBMTR schema, stratifie
receiving a URD transplant.going HCT in CR1 or CR2. This scheme divides
patients with abnormal karyotypes into 3 groups: a fa-
vorable group [inv(16)], an adverse group (complex
karyotype, which may be optimally defined in the
HCT context as 4 or more abnormalities), and an
intermediate group comprising all other classified
abnormalities, which has an outcome similar to that
of normal karyotype.
Several limitations of this study must be consid-
ered. Due to its retrospective nature, the study was
subject to the selection bias of patients chosen to re-
ceive HCT. This is particularly relevant for patients
with CBF AML, who do not commonly undergo
HCT while in CR1. There were not significantly
more patients with a WBC count .20  109/L at di-
agnosis in the t(8;21) or inv(16) subgroup compared
with normal karyotype; however, it is quite possible
that the patients in this study had other, undefined ad-
verse features associated with the decision to perform
HCT (eg, leukemia cutis, number of regimens needed
to reach CR). It is nonetheless reassuring that a favor-
able subgroup could still be identified, and that the
classification is applicable to both patients in CR1
and in CR2 (see Figure 2), because HCT may be con-
sidered standard therapy for CBF AML inCR2.More-
over, this retrospective study has the advantage of the
observational database of the CIBMTR, which pro-
vides realistic data reflecting current practice and
allows for a variety of heterogeneous factors to be
potentially neutralized [18].d by donor type. (A) Patients receiving an MRD transplant. (B) Patients
Figure 4. OS of patients classified according to the CIBMTR schema, stratified by conditioning intensity. (A) Patients undergoing transplantation with
myeloablative conditioning. (B) Patients undergoing transplantation with RIC.
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preted as a direct comparison of HCT and con-
ventional chemotherapy outcomes. Although it is
tempting to conclude from this study that patients
with abnormal karyotypes that are considered
adverse under most conventional schemes but inter-
mediate under the CIBMTR scheme (eg, abnormal
5 or 7) should be considered for HCT in CR1, our
data do not directly address this inference. In this
respect, it should be remembered that the survival
curves presented here depict the outcomes of pa-
tients undergoing HCT, and are not comparable to
intent-to-treat curves for cohorts of patients with
newly diagnosed AML.
This study could not incorporate anymolecular in-
formation (eg, c-Kit, FLT3, NPM-1 status); minimal
residual disease status; cytogenetic remission informa-
tion that was not available in our dataset. The
relevance of karyotypically silent mutations is now
beyond dispute [19], although their relevance in the
HCT setting is not well understood. Certainly the
present scheme could be refined in the future by incor-
porating mutation status, which would be a very
important step forward in defining prognostic sub-
groups for patients with AML undergoing HCT.
Gene–gene interactions involving both mutations
and karyotype also may be important in the biology
of leukemia [20]; their relevance in the HCT setting
may be addressed when a large population of HCT
recipients with complete karyotype and molecular
information is available.
Our study cohort was not large enough to allow
an independent validation cohort. However, the
CIBMTR scheme performed well in the (independent)
cohort that we used previously to establish the DFCI
schema. Also noteworthy is the close similarity of
the CIBMTR and the DFCI schemes (weighted k sta-
tistic 5 0.73); the only differences are the assignment
of isolated t(8;21) (intermediate here and favorable in
DFCI), and the definition of complex karyotype ($4
abnormalities here versus$3 in DFCI; note, however,
that the optimal definition of complex karyotype wasnot studied in the DFCI scheme). The CIBMTR
andDFCI schemes were derived in 2 entirely indepen-
dent patient cohorts and yielded essentially the same
results. This provides an external validation of the
CIBMTR scheme, with the exception of isolated
t(8;21), whose exact place remains to be confirmed in
future studies. One study has suggested that t(8;21) is
not as favorable as inv(16) after HCT [21], in agree-
ment with our findings.
Finally, it is possible that a 3-group cytogenetics
classification underestimates the complexity of the
problem, and that a much larger study could subdivide
karyotypes further, as well as elucidate the prognostic
importance of rare karyotypic abnormalities that were
underrepresented in our dataset. For example, it ap-
pears that a complex karyotype with 4 abnormalities
is less adverse than one with 5 or more abnormalities.
However, given the challenges associated with re-
viewing primary cytogenetics data in a registry study,
a much larger study might not be practical. It also may
be of interest in the future to examine the prognostic
impact of cytogenetic evolution. Our cohort did not
contain sufficient data to allow us to assess this rigor-
ously. Thus, we chose the abnormal karyotype closest
to the time of transplantation for analysis, because
this is likely to be the best determinant of outcome.
An HCT-specific cytogenetics grouping scheme
such as that proposed here may have several uses. It
may help clinicians and patients better estimate prog-
nosis after HCT, which is often a critical part of the
decision to pursue HCT. In addition, it provides a sys-
tem for stratifying adult patients entering clinical trials
of HCT for AML. Indeed, in our cohort (as in a previ-
ously reported one [11]), cytogenetics was the single
most important determinant of patient outcome,
underscoring the importance of cytogenetics stratifica-
tion in clinical trials. This highlights the need to strat-
ify patients in clinical trials and provides a means for
doing so. Similarly, this scheme could help compare
outcomes across different HCT studies or across
institutions, which has become essential in the era of
mandatory outcome reporting.
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